Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00923806 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00923806: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00923806 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00923806, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Background: * Carcinoembryonic antigen (CEA) is a protein present mostly in cancer cells. * An experimental procedure developed for treating patients with cancer uses blood cells found in their tumors or bloodstream. These cells are genetically modified using the anti-CEA gene and a type of virus. The modified cells (anti-CEA cells) are grown in the laboratory and then given back to the patient to try to decrease the size of the tumors. This is called gene therapy. Objectives: * To determine whether advanced cancers that that express the CEA antigen can be treated effectively with lymphocytes (white blood cells) that have been genetically engineered to contain an anti-CEA protein. Eligibility: * Patients 18 years of age and older with metastatic cancer (cancer that has spread beyond the original site) and for whom standard treatments are not effective. * Patients' tumors express the CEA antigen. * Patients have the human leukocyte (HLA-A\*0201) antigen. Design: * Workup with scans, x-rays and other tests. * Leukapheresis to obtain cells for preparing the anti-CEA cells for later infusion. * 1 week of chemotherapy to prepare the immune system for receiving the anti-CEA cells. * Infusion of anti-CEA cells, followed by interleukin-2 (IL-2) treatment. The cells are given as an infusion through a vein. IL-2 is given as a 15-minute infusion through a vein every 8 hours for a maximum of 15 doses. * 1-2 weeks of recovery from the effects of chemotherapy and IL-2. * Periodic follow-up clinic visits after hospital discharge for physical examination, review of treatment side effects, laboratory tests and scans every 1 to 6 months.
Interventions
- DRUG Aldesleukin
- BIOLOGICAL PG13-CEA_TCR (Anti-CEA TCR PBL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Why NCT00923806 stopped before completion
NCT00923806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Aldesleukin is the first listed.
NCT00923806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00923806 about?
NCT00923806 is a clinical study titled "Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer". Background: * Carcinoembryonic antigen (CEA) is a protein present mostly in cancer cells. * An experimental procedure developed for treating patients with cancer uses blood cells found in their tumors or bloodstream. These cells are genetically modified using the anti-CEA gene and a type of virus. ...
What is the current status of trial NCT00923806?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-12. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00923806?
The interventions under investigation include: Aldesleukin (DRUG), PG13-CEA_TCR (Anti-CEA TCR PBL) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00923806?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00923806's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia